BriaCell Therapeutics Corp.’s Post

BriaCell reported an influx of cancer fighting CD8+ “killer” T cell into #metastaticbreastcancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria-IMT™ + CPI. https://bit.ly/3ORaBfF #SABCS24 #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell's advanced imaging technology confirms clinical responses seen in #metastaticbreastcancer correlate with increase in CD8+ “killer” T Cells in lesions and lymph nodes. https://bit.ly/3ORaBfF #SABCS24 #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) highlights the infiltration of cancer fighting immune cells into tumors, using leading CD8 ImmunoPET imaging technology, in its poster presentation at the 2024 San Antonio Breast Cancer Symposium® at Henry B. Gonzalez Convention Center, San Antonio, TX. Find details: https://bit.ly/3ORaBfF #SABCS24 #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

Our innovative Affibody® molecules can be attached to radioactive agents for precise tumor targeting. Once injected, these molecules quickly find and bind to specific surface proteins on cancer cells, where they remain to deliver highly focused radiation. This precision minimizes damage to healthy tissue and helps initiate the body's immune system to detect and kill any remaining cancer cells. This unique mechanism offers potential for combination therapies with immuno-oncology drugs. In collaboration with esteemed academic institutions and GE HealthCare, we are driving progress in oncology with leading candidates ABY-025 and GE-226, PET tracers that enable non-invasive imaging of HER2 expression in cancers like breast and gastric cancer. These tracers help detect HER2 levels and monitor therapy response, expanding treatment options for more patients. Learn more about our pipeline: https://lnkd.in/dukR7hcG #Oncology #Antibodies

Advanced ImmunoPET imaging technology correlates with clinical benefit with the Bria-IMT™ combination regimen in metastatic breast cancer and suggests possible use in identifying #immunotherapy responsive tumors. These findings support the continued use of the Bria-IMT™ combination regimen in BriaCell’s ongoing pivotal Phase 3 study (listed on ClinicalTrials.gov as NCT06072612) in MBC. https://lnkd.in/eQKzT-di #SABCS24 #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

TCR therapy Market (T-cell receptor therapy) is a type of immunotherapy that harnesses the body’s T cells to target and attack cancer #cells. It involves modifying T cells to express specific receptors that recognize cancer-associated antigens, enhancing the immune response against tumors. The market for TCR therapy is growing due to increasing #cancer prevalence and advancements in personalized medicine. Get more on: https://lnkd.in/dbeYKdHK #TCRTherapy #Immunotherapy #CancerTreatment #PersonalizedMedicine #CellTherapy #CancerResearch #Biotech #Oncology #ClinicalTrials

Immunophotonics, Inc. is excited to be featured in Pharma Tech Outlook magazine in the Immunotherapy edition. Immunophotonics innovative approach could transform standard treatments into powerful immunotherapies with IP-001 turning every procedure into an opportunity to mobilize the body’s natural immune system against cancer.   Check out the article “A New Frontier in Treating Cancer: The Great Potential of Interventional Immuno-Oncology™.  Link to article: https://lnkd.in/gcZ2gS8M Visit us at: www.immunophotonics.com #research #interventionaloncology #immunooncology #cancer #immunotherapy #Immunophotonics #clinicaltrials #innovation #abscopalize_it #oncology #oncologyresearch #interventionalradiology #medicaloncology #trials #healthcareexcellence #biotechnology #drugdevelopment #antibody #cancerimmunity #immunophotonics 

BriaCell’s President and CEO, Dr. William V. Williams, emphasizes the significant potential of our personalized and off-the-shelf cancer therapy, Bria-OTS™ in patients with melanoma, prostate and lung cancers. Learn more: https://bit.ly/3V1asJY #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

🔍 Deep-Dive into Breast Cancer Multi-Gene Assays 🔬 Elevate your expertise in breast cancer diagnostics by viewing our on-demand webinar "A Practical Guide to Understanding Breast Multi-Gene Assays." Discover the most widely used multi-gene assays, learn the distinctions among them, and gain practical insights to enhance patient care. 🎯 Learning objectives: • Understand the theory and purpose behind each assay. • Explore differences and clinical scenarios for test selection. • Identify appropriate tumor types and samples for each test. Earn 1.0 CMLE and 1.0 AMA PRA Category 1 credit! REGISTER:🔗 https://ow.ly/8tCE50U3zze This is Part 1 of our Breast Cancer Molecular Testing series. Don't miss out! #BreastCancer #MolecularTesting #Webinar

Read this featured research on T-cell immunotherapy! 🎉 A new study in Nature Communications shows how BPS Bioscience Inc. 's MART1-Specific TCR Lentivirus (Clone DMF5) helped create a Jurkat cell line with T Cell Receptors that target the melanoma-associated MART-1 antigen. This tool was key in studying antigen-specific T cell activation using the ATLAS-seq platform—marking important progress in engineered T cell immunotherapies. It’s incredible to see how these tools are enabling this ground-breaking research in cancer immunotherapy and beyond. 🔬✨ https://lnkd.in/drj5BcJv #Immunotherapy #CancerResearch #TCells #Bioscience